Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.

Abstract	A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alrestatin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive skin rash.
Authors	D J Handelsman, J R Turtle
Journal	Diabetes (Diabetes) Vol. 30 Issue 6 Pg. 459-64 (Jun 1981) ISSN: 0012-1797 [Print] United States
PMID	6785131 (Publication Type: Clinical Trial, Journal Article)
Chemical References	Glycosides Isoquinolines Placebos alrestatin Hemoglobin A Sugar Alcohol Dehydrogenases Aldehyde Reductase
Topics	Action Potentials Adult Aged Aldehyde Reductase (antagonists & inhibitors) Clinical Trials as Topic Diabetic Neuropathies (drug therapy) Female Glycosides (analysis) Hemoglobin A (analogs & derivatives, analysis) Humans Isoquinolines (therapeutic use) Male Middle Aged Motor Neurons (physiology) Muscles (innervation, physiopathology) Placebos Sugar Alcohol Dehydrogenases (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!